Role of CD8-positive cells in radioimmunotherapy utilizing Lu-mAbs in an immunocompetent rat colon carcinoma model by unknown
Elgström et al. EJNMMI Research  (2015) 5:3 
DOI 10.1186/s13550-014-0079-6ORIGINAL RESEARCH Open AccessRole of CD8-positive cells in radioimmunotherapy
utilizing 177Lu-mAbs in an immunocompetent rat
colon carcinoma model
Erika Elgström1*, Sophie E Eriksson1, Tomas G Ohlsson2, Rune Nilsson1 and Jan Tennvall1,3Abstract
Background: CD8-positive cells might play a crucial role in the therapeutic response to radiation, which has however
not been investigated in radioimmunotherapy (RIT). The aim of this study was to evaluate whether cytotoxic T cells
affect the response of established tumors and, above all, if they delay or prevent the development of distant
metastases after RIT, using an immunocompetent syngeneic rat colon carcinoma model.
Methods: The cytotoxic T cells were depleted in 15 rats by anti-CD8 before the injection of the radioimmunoconjugate
(400 MBq/kg body weight 177Lu-BR96, which binds to the tumor-associated antigen Lewis Y). Fifteen other rats were
treated with RIT only. Both groups were followed for 99 days. Blood samples were collected at least once weekly, and
tumors were monitored twice weekly.
Results: Twenty-nine of the 30 animals exhibited local complete response. The non-responder was treated with
anti-CD8 and RIT but succumbed later due to metastases. Five animals in the group given anti-CD8 + RIT were
sacrificed due to metastatic disease, and 4 additional animals were found to have metastases at autopsy. In the
group given RIT, 4 animals developed metastatic disease, but no metastases were found in the remaining 11 animals
at autopsy. Thus, at the end of the study, 6 animals in the anti-CD8 + RIT group were free from metastases, while 11
were free from metastases in the group receiving RIT.
CD3+CD4−CD8+ lymphocytes were consistently depleted by the anti-CD8 treatment. The myelosuppression was
otherwise similar in the two groups. The initial depletion of CD8-positive cells in our syngeneic rat colon carcinoma
model resulted in a higher frequency of animals developing metastases.
Conclusions: Depletion of CD8-positive cells during RIT in an immunocompetent rat tumor model might influence
the number of animals developing metastases, indicating that the immune system may be important in the long-term
outcome of RIT.
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The treatment of primary tumors is often successful,
while metastatic disease still poses a considerable chal-
lenge. The vast majority of cancer-related deaths are the
direct or indirect effect of distant metastases [1]. Novel
modes of treatment are therefore needed to reduce or
delay the development and growth of distant metastases.* Correspondence: Erika.Elgstrom@med.lu.se
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in any medium, provided the original work is pRadioimmunotherapy (RIT) utilizes antibodies to dir-
ect radionuclides to specific antigens within the tumor.
Using our immunocompetent syngeneic rat colon car-
cinoma model, we have previously shown that RIT
consisting of the beta emitter 177Lu (400 MBq/kg body
weight) conjugated to the monoclonal antibody BR96 re-
sulted in complete response in 17 of 19 animals [2]. In
the same study, cyclosporin A, a substance known to
have its major effects on T cells [3-8], was given to pre-
vent the development of immune response to the thera-
peutic mouse/human chimeric antibody. Treatment with
cyclosporin A prolonged the time to complete responses an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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tion of animals exhibiting complete response was simi-
lar. Neither the time to metastatic disease nor the
fraction of animals developing disseminated disease was
affected by cyclosporin A. This observation indicates
that T cells might be involved in the response process of
RIT in our model.
Others have shown that the depletion of cytotoxic T
cells by the administration of anti-CD8 antibodies re-
verses the anti-tumor effects of external-beam radiation
therapy [9-12], which indicates that CD8-positive cells
play a crucial role in the therapeutic response to radi-
ation in these models. These findings motivated us to
perform the present study to evaluate the effects of cyto-
toxic T cells on the response of established tumors and
to establish whether they prevented the development of
distant metastasis after RIT in our immunocompetent syn-
geneic rat colon carcinoma model. Half of the animals
were given anti-CD8 on two occasions and all the animals
were given RIT (400 MBq/kg body weight 177Lu-BR96). To
the best of our knowledge, the role of CD8-positive cells
during RIT has not previously been investigated.
Methods
Anti-CD8 antibodies
The OX-8 cell line (Health Protection Agency Culture
Collections) producing a murine anti-CD8 monoclonal
antibody was grown in CD Hybridoma Medium (Gibco,
Life Technologies, Carlsbad, CA, USA) supplemented
with 2 mML-glutamine and 2.8 mg/L gentamicin (PAA
Laboratories GmbH) for 10 to 12 days. The medium was
centrifuged, and the supernatant was collected and
stored at −20°C. The antibodies were purified utilizing
HiTrap™ Protein A HP columns (GE Healthcare Life
Sciences, Uppsala, Sweden), and the eluted antibodies were
transferred to phosphate-buffered saline (PBS, Sigma-
Aldrich, St. Louis, MO, USA) by repeated centrifugation
using an Amicon-15 filter unit (molecular weight cutoff
30,000, Millipore, Billerica, MA, USA). The purity of
the antibody solution was analyzed by bioanalyzer and
a Protein 230 plus kit (Agilent Technologies, Santa
Clara, CA, USA). The protein concentration was deter-
mined using the BCA (bicinchoninic acid) standard assay
(Sigma-Aldrich, St. Louis, MO, USA). The purified anti-
body solution was stored at −20°C.
The therapeutic monoclonal antibody
The chimeric (mouse/human) monoclonal IgG1 anti-
body BR96 (Seattle Genetics Inc., Bothell, WA, USA),
which binds to the tumor-associated antigen Lewis Y,
was used in this study. The Lewis Y antigen is expressed
on the majority of human epithelial tumors, but normal
human tissue also contains the BR96-binding antigen,
primarily in the epithelial cells of the gastrointestinaltract [13]. The binding affinity between BR96 and the
carcinoma cell line used in this study is strong (the dis-
sociation constant being 4 nM) [14].
Radioimmunoconjugation
Conjugation was performed according to Forrer et al.
[15]. Briefly, BR96 was transferred to 0.2 M sodium car-
bonate buffer, pH 9.5, by repeated centrifugation using
the Amicon-15 filter unit. The DOTA-chelate (S-2-
(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane
tetraacetic acid; 2 mg/mL H2O, Macrocyclics, Dallas, TX,
USA) was added to the BR96 antibody (100 mg/mL) at a
molar ratio of 3:1 (DOTA:BR96) and incubated for 1 hour
at 37°C. The conjugate was purified by repeated centrifuga-
tion as described above and transferred to 0.25 M ammo-
nium acetate buffer, pH 5.3. The final concentration was
adjusted to 10 mg/mL BR96 by the addition of ammonium
acetate buffer. All vials were pretreated with 1% HNO3
and all buffers were pretreated with Chelex-100 (Bio-Rad,
Hercules, CA, USA) to remove metals.
MALDI-MS was used to determine the number of
DOTA moieties per BR96 molecule, by desalting the
sample to 18 MΩ · cm H2O using a centrifugation filter
device, and dividing the increase in molecular mass by
the molecular mass of the DOTA-chelate (688 u).
Both the 177LuCl3 solution (MDS Nordion, Ottawa,
Canada) and the DOTA-BR96 conjugate in 0.25 M am-
monium acetate buffer were preheated to 45°C for
10 min. The DOTA-BR96 solution was added to the vial
containing the radionuclide and incubated at 45°C for
15 min. The reaction was quenched with an excess of
DTPA (diethylene triamine pentaacetic acid) for 5 min.
The radiolabeled immunoconjugate was diluted in 1%
human serum albumin (HSA, Baxter, Deerfield, IL, USA)
to prevent radiolysis from affecting the immunoreactivity.
The radiochemical purity was determined by instant thin-
layer chromatography (ITLC) using a 1 × 9 cm silica-gel-
impregnated fiberglass sheet as the solid phase and
0.1 M EDTA as the mobile phase. To confirm the
radiochemical purity and to detect signs of aggregation
or fragmentation, separation was performed using size-
exclusion chromatography and high-performance liquid
chromatography (HPLC) (using a 7.8 × 300 mm molecular
sieving column, Phenomenex SEC S3000 (Phenomenex,
Torrance, CA, USA), eluted with 0.05 M sodium phos-
phate at 1.0 mL/min).
Syngeneic animal model
BN7005-H1D2 is a cell line established from a 1,2-
dimethylhydrazine-induced rat colon carcinoma in the
Brown Norway (BN) rat. The cells were cultured in
RPMI-1640 medium supplemented with 10% fetal calf
serum, 1 mM sodium pyruvate, 10 mM HEPES buffer, and
14 mg/L gentamicin (all from PAA Laboratories GmbH) at
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The cells were washed in PBS and detached by treatment
with trypsin (both from PAA Laboratories GmbH). We
have previously determined the radiosensitivity of this cell
line, expressed as the fraction of survival after exposure to
2 Gy (S2Gy), to be 0.5 (
137Cs radiation source, unpublished
data). This is similar to the radiosensitivity of human colo-
rectal carcinoma cell lines [16].
BN rats are immunocompetent and express the BR96
binding antigen in normal tissues, mainly in the epithe-
lium of the gastrointestinal tract [17], similar to humans.
The animals were inoculated with 3 × 105 cells between
the peritoneum and the abdominal wall under anesthesia
(Isoflurane, Baxter). All experiments were conducted in
compliance with European legislation on animal welfare
and were approved by the Regional Animal Ethics Com-
mittee. The animals were housed under standard condi-
tions and fed with standard pellets and fresh water ad
libitum.
Radioimmunotherapy and depletion of CD8-positive cells
The amount of administered anti-CD8 required for effi-
cient depletion, suggested by Holmdahl et al. and Huang
et al. [18,19], was confirmed by i.v. injection of 0.5 or
1.0 mg anti-CD8 (in 0.4 mL saline) in 6 tumor-free BN
rats. The animals were followed for 25 days p.i., and
blood samples were collected twice a week.
On day 0 (13 to 14 days after cell inoculation), 15
tumor-bearing BN rats in the RIT group, were given
400 MBq/kg 177Lu-BR96 (150 μg DOTA-BR96 in 0.4 mL
saline with 1% HSA) by intravenous injection. In the
anti-CD8 + RIT group, 15 tumor-bearing BN rats were
given anti-CD8 on day −3 (0.5 mg in 0.4 mL saline) and
day 9 (0.3 mg in 0.4 mL saline), and 400 MBq/kg body
weight 177Lu-BR96 day 0. The tumors were measured
using a caliper, and the tumor volumes were calculated
as (tumor length × tumor width2 × 0.4) [20]. The median
tumor volume of all animals on day 0 was 680 mm3
(interquartile range 460 mm3), and the median body
weight on day 0 was 272 g (interquartile range 22 g). Body
weight and tumor volume were measured twice a week.
Blood samples were collected from all animals to monitor
myelosuppression and for flow cytometric analyses of
CD8-positive cells twice weekly from one week before in-
jection and during the first 4 weeks after injection of the
radioimmuno-conjugate, and then once weekly until the
end of the study (day 99) or sacrifice. The study was ended
99 days p.i., as in our previous study lasting 180 days all
metastatic disease was detectable within 100 days p.i. [21].
Animals were sacrificed and dissected if the tumor size
approached 20 × 20 mm, if the decrease in body weight
approached 20% of the normal weight progression, if the
general health of the animal was affected during the
study, or if metastatic disease was suspected. All remaininganimals were sacrificed and dissected at the end of the
study (day 99). All dissections were performed by the same
person (EE) and the location of metastases was recorded.
Blood analyses
Blood samples were used to evaluate the total number of
white blood cells, as a measure of myelosuppression,
and the CD3+CD4−CD8+ lymphocytes in order to moni-
tor CD8-positive cells. Myelosuppression was deter-
mined by counting the white blood cells and platelets
with a Vet CA530 Medonic Cell Analyzer (Boule Medical,
Spanga, Sweden).
In order to label CD3/CD4/CD8a in blood, EDTA-
treated blood samples were incubated with mouse anti-
rat CD32 (BD Pharmingen) for 15 min to achieve FcR
blockage and stained with FITC-conjugated anti-rat
CD3, PE-conjugated anti-rat CD4, and Alexa Fluor 647-
conjugated anti-rat CD8a (all from Biolegend, San Diego,
CA, USA) for 30 min. Red blood cells were lysed with
Erythrolyse Red Blood Cell Lysing Buffer (AbD Serotec,
Oxford, UK), and fixed in 0.5% PFA (paraformaldehyde) in
PBS/BSA (10 g BSA in 1 L PBS). Labeled cells were ana-
lyzed on the same day.
Samples were analyzed with a FACSCalibur flow
cytometer (BD Bioscience, San Jose, CA, USA) using
CellQuest Pro collection software (BD Bioscience). Cor-
rections were made for spectral overlap. One hundred
thousand events per sample were recorded. The collected
data were analyzed with Flowing Software 2.5.0 (P. Terho,
University of Turku, Finland). CD3+ lymphocytes were
gated using forward scatter, side scatter, and FITC chan-
nels. CD4−CD8+ cells were counted in both the lympho-
cyte gate (in the forward scatter and side scatter plot) and
CD3+ lymphocyte gate.
Statistical analysis
The risk of developing metastases was calculated using a
log-rank test (Cox-regression) with the STATA software
(StataCorp LP, College Station, Texas, USA), while time to
complete response of the local tumor (Mantel-Cox test)
was calculated using Prism 5.02 (GraphPad Software Inc.,
La Jolla, CA, USA).
Results
Radioimmunoconjugate
The number of DOTA moieties per BR96 molecule was
2.6. After radiolabeling, the specific activity of the 177Lu-
DOTA-BR96 conjugate was 675 MBq/mg. ITLC showed
the radiochemical purity to be 95% and 4% aggregates or
fragments were observed with HPLC.
Local tumor response
All animals in the RIT group exhibited local complete
response, defined as non-palpable tumor and no detectable
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animals but one showed local complete response, al-
though this tumor initially responded well to the treat-
ment (reduction in tumor volume of 99%). The animal
not showing local complete response was sacrificed due
to metastatic disease on day 45. There was no statistical
difference between the groups regarding time to local
complete response (Mantel-Cox test). Individual tumor
volumes are presented in Figure 1.
Disseminated disease
Five of the 15 animals in the anti-CD8 + RIT group were
sacrificed due to loss of body weight (on days 28, 42, 45,
91, and 96), and metastases were verified in all these ani-
mals at subsequent autopsy. The autopsy performed at
the end of the study revealed metastases in 4 additional
animals, but the remaining 6 animals were free from de-
tectable metastases. Four of the 15 animals in the RIT
group were sacrificed due to loss of body weight (on
days 56, 84, 91, and 91), metastases being verified atFigure 1 Tumor volume growth after treatment. Individual
(black) and average (red bold) tumor volumes in animals treated with
anti-CD8 + RIT (above) and in animals treated with RIT only (below).autopsy. All the remaining animals in this group were
free from detectable metastases at the end of the study
(there were no significant difference between the two
groups, Mantel-Cox test p = 0.11); in the RIT group, it is
expected to find metastases up to 100 days after admin-
istration of radioimmunoconjugate according to our pre-
vious study [21], indicating that metastases do not
develop later. Thus, 99 days after injection of the radio-
immunoconjugate, 11 animals in the RIT group were
free from detectable metastases, while only 6 were free
from detectable metastases in the anti-CD8 + RIT group
(Figure 2, Table 1).
The hazard for developing metastases at day 99 was
2.5 times higher in the anti-CD8 + RIT group than in the
RIT group [hazard = 2.5, 95% confidence interval (CI)
0.76 to 8.0, p = 0.13]. The corresponding odds ratio was
4.1 [[(9/6)/(4/11)] 95% CI 0.88 to 19, p = 0.07]. Metasta-
ses were found in surgical scar (1 animal), abdominal
lymph nodes (2 animals), mesentery (2 animals), retro-
peritoneal space (2 animals), abdominal cavity (6 animals),
lungs (7 animals), and upper thoracic lymph nodes (11 ani-
mals). No difference in location was observed between the
two treatment groups. No animal was sacrificed due to the
side effects of treatment.
Myelosuppression and the effect of anti-CD8
Both 0.5 and 1.0 mg anti-CD8 antibodies completely de-
pleted the CD3+CD4−CD8+ lymphocytes in the blood on
the day after injection. Eight days after injection, the
CD3+CD4−CD8+ lymphocytes started to recover, and
there was still no difference between the two dosages. For
0.5 mg, the average %CD3 +CD8+ of CD3+ lymphocytesFigure 2 Curve of metastatic disease. Fraction of rats with
observed metastatic disease in RIT (solid line) and anti-CD8 + RIT
group (dashed line) during the study period including results of
autopsy at the end of the study. Day 0 = day for injection of
177Lu-DOTA-BR96 treatment.










RIT, n = 15 4 0 11
Number of animals with symptomatic metastatic disease (verified at autopsy),
metastatic findings at autopsy on day 99 (end of the study), and the animals
free from detectable metastases in the two groups (anti-CD8 + RIT and RIT).
Figure 4 Effects on CD8+ cells after treatment. The average of %
CD3+CD4−CD8+ of CD3+ lymphocytes in the RIT group (solid line)
and in the anti-CD8 + RIT group (dashed line). The error bars represent
standard deviation.
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The corresponding results the day after administration was
0.09 and 0.06, respectively, 11 days after administration 5.6
and 5.9 and 25 days 9.2 and 8.0. We decided therefore for
the main study to repeat the administration but with a
lower amount of anti-CD8 given on day 9 to prolong the
depletion of CD3+CD4−CD8+ lymphocytes.
In the main study, the myelosuppression was similar
in the two groups, both in terms of severity and of dur-
ation; see Figure 3. All animals in the anti-CD8 + RIT
group exhibited depletion of CD3+CD4−CD8+ lympho-
cytes on day 0. The RIT group showed an increase in %
CD4−CD8+ of all CD3+ lymphocytes as a result of the
therapy. At the end of the study, both groups had similar
values of %CD4−CD8+ of CD3+ lymphocytes, as can be
seen in Figure 4.
The majority of the animals in the anti-CD8 + RIT
group showed a linear relationship between CD4+ and
CD8+ (double-positive lymphocytes) within the lympho-
cyte gate during the recovery of CD8+ cells, as shown in
Figure 5. The majority of these cells were not CD3+, and
this cell type (CD3−CD4+CD8+) was seen from the timeFigure 3 Myelosuppression after treatment. White blood cells
in animals treated with RIT (solid line) and animals treated with
anti-CD8 + RIT (dashed line). The error bars represent the
standard deviation.of recovery of lymphocytes and the duration varied from
a couple of weeks until the end of the study period. This
type of cell was not seen in animals receiving RIT only.
Discussion
We have found that an early depletion of CD8-positive
cells during RIT seemed to result in the development of
metastases, as demonstrated by the earlier and higher
frequency of metastases in the anti-CD8 + RIT group
(hazard = 2.5, p = 0.13, and odds ratio = 4.1, p = 0.07). At
the end of the study (99 days post therapy), 6 of 15 ani-
mals treated with anti-CD8 + RIT were free from distant
metastases, compared to 11 of 15 animals treated with
RIT. However, the depletion of CD8-positive cells did
not affect the response of established tumors after RIT;
probably, the response of the tumor was dependent on
the irradiation rather than induction of an immune
response. Our interpretation is that CD8-positive cells
may play a more important role in preventing or delay-
ing the development of microscopic metastases than in
the regression of already established tumors.
Treatment with anti-CD8 + RIT did not increase mye-
losuppression compared to RIT alone in the present
study. We found that anti-CD8 + RIT induced double-
positive lymphocytes (CD4+CD8+) during the recovery
of the lymphocytes, seen as a linear relationship between
CD4+ and CD8+ cells within the lymphocyte gate in flow
cytometry analyses (Figure 5). This may indicate a leak-
age of immature T cells from the thymus. CD4+CD8+
cells are a normal finding in the thymus [22-26]; they
can be present in the circulation in healthy individuals
[27,28] and at a higher proportion in some diseases,
Figure 5 Flow cytometric findings during the recovery of CD8+cells in anti-CD8-treated animals. Dot plots from the same animal treated
with anti-CD8 + RIT, CD4−CD8+ cells labeled red. A to C illustrates all lymphocytes, and D to F illustrates CD3+ lymphocytes. A, D Untreated, 1 week
before administration of radioimmunoconjugate (day −7). B, E 70 days after injection of radioimmunoconjugate. C, F 98 days after injection
of radioimmunoconjugate.
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that these cells can be induced by antibodies to CD8 or
CD4 [29], but it is not known whether these CD4+CD8+
cells are functionally active. We did not observe any
symptoms or signs of autoimmune disorders during
the 102 days of follow-up after the first injection of
anti-CD8. In the RIT group, no double-positive cells
(CD4+CD8+) were detected, but the total number of
CD8+ cells was also reduced in the RIT group due to mye-
losuppression by irradiation from the RIT. However, the
reduced number was still sufficient to prevent to a certain
extent metastases, as the animals in the anti-CD8 + RIT
group had a higher risk of developing metastases. Thesecond administered dose of anti-CD8 was given with the
intention to prolong the depletion of CD8-positive cells
and delay the recovery. The lack of further depletion of the
second administration might be due the possibility of the
induction of rat anti-mouse antibodies, which were unfor-
tunately not evaluated.
In the present study, we administered an activity of
400 MBq/kg body weight, which results in mean absorbed
dose rates of approximately 0.2 to 0.6 Gy/h at the maximal
uptake, 24 h p.i. [30]. To the best our knowledge, no study
has evaluated the effect of CD8 lymphocytes on the
therapeutic outcome of RIT. Studies evaluating the role of
CD8-positive cells during external-beam radiation therapy
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of fractionation and the administered dose must be carried
out [31,32]. Gough et al. have shown that a single fraction
of 20 Gy in 3LL (Lewis lung carcinoma)-bearing mice
significantly decreased the number of CD8-positive
tumor-infiltrating cells within 2 days after radiation,
but with a significantly higher fraction of CD8-positive
cells infiltrating the tumor 7 days after radiation [10]. They
also found that depletion of CD8 T cells prior to radiother-
apy (20 Gy given three times over 10 days) significantly
decreased the median survival compared to radiotherapy
without CD8 depletion [10]. Lee et al. showed that the
therapeutic results of a single dose of 20 Gy in B16 tumors
were almost abrogated by CD8 depletion. A single fraction
of irradiation has been found to significantly increase
tumor regression in immunocompetent mice, but not in T
cell-deficient mice, and an increase in T cells infiltrating
the tumor microenvironment was seen 1 to 2 weeks after
the treatment [11]. In another study, TUBO tumors in
SCID mice were found to be less responsive to radiation
than TUBO tumors in immunocompetent BALB/c mice
[9]. The tumors in these immunocompetent animals
treated with anti-CD8 antibody and radiation continued
to grow, while tumor growth was inhibited in animals
treated with radiation only [9]. Yoshimoto et al. reported a
significant decrease in the therapeutic efficiency of radi-
ation and significantly shortened survival time in animals
treated with 30 Gy and anti-CD8 [12]. The findings of
these animal studies demonstrate that CD8-positive cells
are involved in the therapeutic effects of radiation.
There can be a difference in the biological effects
of external and internal radiation which can influence
CD8-positive cells differently. External radiation is ad-
ministrated at high dose rate during a short time, often
repeated, whereas RIT radiation is administrated at a
low-dose rate continuously for a longer time. This con-
tinuous decay may also inhibit the lymphocyte activity
within the tumor. In the present study, we focused on
CD8-positive cells, but lymphocytes are sensitive to low
doses of irradiation [33-35]. Macrophages, NK cells, and
DCs are more resistant to radiation [33,34], but their
role might also be important in RIT and they should
therefore be further investigated.
Conclusions
The depletion of CD8-positive cells in our syngeneic rat
colon carcinoma model seemed to result in a higher fre-
quency of animals developing distant metastases, thus in-
dicating that cytotoxic T cells participate in an immune
response to the tumor. This finding indicates that future
investigations should be undertaken combining RIT with
immunotherapy to delay or prevent development of dis-
tant metastases. These cytotoxic T cells did not seem to
have any major effect on already established tumors.Abbreviations
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